BridgeBio Oncology Therapeutics Inc. (BBOT) — Financial statements
Income statement, balance sheet, and cash flow for BridgeBio Oncology Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 121↑65.8% | 73↑29.9% | 56 | 0.00 | 0.00 | |
| General & Administrative Expenses | 25↑217.4% | 8↓8.6% | 8↑240951.1% | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 25↑217.4% | 8↓8.6% | 8↑240951.1% | 0.00↓91.9% | 0.04 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 146↑80.3% | 81↑24.8% | 65↑1839985.2% | 0.00↓91.9% | 0.04 | |
| Total Costs & Expenses | 146↑80.3% | 81↑24.8% | 65↑1839985.2% | 0.00↓91.9% | 0.04 | |
| Operating Results | ||||||
| Operating Income | -146↓80.3% | -81↓24.8% | -65↓1839985.2% | -0.00↑91.9% | -0.04 | |
| Depreciation & Amortization | 0.61↑193.3% | 0.21↑126.1% | 0.09 | 0.00 | 0.00 | |
| EBITDA | -145↓80.0% | -81↓24.7% | -65↓1837371.6% | -0.00↑91.9% | -0.04 | |
| EBIT | -146↓80.3% | -81↓24.8% | -65↓1839985.2% | -0.00↑91.9% | -0.04 | |
| Interest & Other Income | ||||||
| Net Interest Income | 11↑34.1% | 8↑11643.7% | 0.07 | 0.00 | 0.00 | |
| Interest Income | 11↑34.1% | 8↑11643.7% | 0.07 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 12↑43.9% | 8↑11266.5% | 0.07 | 0.00 | 0.00 | |
| Income Before Tax | -134↓80.5% | -74↓14.8% | -65↓1837939.8% | -0.00↑91.9% | -0.04 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -134↓1863.9% | 8↑111.7% | -65↓1837939.8% | -0.00↑91.9% | -0.04 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -134↓80.5% | -74↓14.8% | -65↓1837939.8% | -0.00↑91.9% | -0.04 | |
| Bottom-Line Net Income | -134↓1863.9% | 8↑111.7% | -65↓1837939.8% | -0.00↑91.9% | -0.04 | |
| EPS (Basic) | -4.30↓1034.8% | 0.46↑23100.0% | -0.00↓1100.0% | 0.00↑109.5% | -0.00 | |
| EPS (Diluted) | -4.30↓1034.8% | 0.46↑23100.0% | -0.00↓122.2% | -0.00↑57.1% | -0.00 | |
| Weighted Average Shares | 31↑87.2% | 17↓18.8% | 20↑0.0% | 20↑0.0% | 20 | |
| Weighted Average Diluted Shares | 31↑87.2% | 17↓18.8% | 20↑0.0% | 20↑0.0% | 20 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.